VivoSim Expands NAMKind Toxicology Services in Asia-Pacific—Targeting Fast, Human-Based Drug Safety Insights

Regional Expansion Brings Human-Based Screening to Korea and China

VivoSim Labs, Inc. (NASDAQ: VIVS), a leader in next-generation New Approach Methodologies (NAMs), has just announced partnerships with JCBio in Korea and Tekon Biotech in China to distribute its NAMKind™ liver and small intestine toxicology services. This agreement puts VivoSim in the heart of Asia-Pacific’s fast-evolving pharmaceutical markets and is designed to offer faster access to drug developers who are under increasing pressure to de-risk programs earlier and accelerate clinical timelines.

Demand for Human-Relevant Testing Hits a Turning Point

The conversation around drug safety testing is shifting rapidly. Drug developers want earlier, more reliable answers—a trend fueled by regulators, cost pressures, and the quest to avoid expensive late-stage failures. VivoSim’s approach delivers exactly that, introducing a streamlined “molecules in, data out” model and reaching a decision-ready data point in about 30 days per study. As shown in the table below, the key differentiator is speed combined with human relevance, especially for challenging liver and gastrointestinal risks.

Regulatory Alignment Accelerates Adoption

Both the Korean MFDS and U.S. FDA are increasingly open to scientifically robust NAM-based evidence to inform drug approval decisions, particularly for the liver and gastrointestinal targets. This regulatory tailwind is critical—making the shift towards NAM methodologies not just a scientific preference, but often a practical requirement for biotech and pharma innovators operating in these regions.

China’s Transformation Fuels Market Demand for Predictive Toxicology

Tekon Biotech aims to introduce VivoSim’s proprietary human tissue models to a Chinese market where preclinical drug safety is increasingly top-of-mind. The China in-vitro toxicology testing market is expected to more than double—from $1.05 billion in 2023 to $2.26 billion by 2030. This surge follows a national pivot from generics toward first-in-class innovative drugs, where reliable, human-relevant data can dramatically reduce risk. Notably, Drug-Induced Liver Injury (DILI) incidence in China stands at 23.80 per 100,000—higher than Western rates—making predictive tools for liver safety mission-critical.

VivoSim’s Platform Addresses Gaps Left by Animal Models

Traditional animal-based toxicity models have proved inadequate at flagging risks associated with advanced modalities—like Antibody-Drug Conjugates (ADCs) and unique compounds in Traditional Chinese Medicine. VivoSim’s NAMKind™ platform is engineered to address these gaps, providing what Tekon Biotech calls “Final Pass Pre-IND” assurance: a data-driven filter to advance only the safest, most promising drug candidates into human trials.

Streamlining Program Execution—and Reducing Costly Failures

With distribution agreements now active, Korean and Chinese clients can access these services locally—supported by JCBio’s regional expertise and Tekon’s broad reach. The goal is a faster, clearer “go/no-go” for each compound, potentially saving millions by prioritizing investment into assets with real-world potential.

Key Takeaway: A Critical Step for Asia’s Accelerating Biotech Sector

VivoSim’s expansion isn’t just about market access—it’s a sign of changing standards as global R&D shifts to human-relevant, high-accuracy platforms. For both innovative startups and established pharma companies in Korea and China, faster, more predictive toxicology means fewer surprises—and potentially millions saved. Investors and industry watchers may want to follow VivoSim’s progress as regulatory landscapes and biotech priorities in Asia continue to evolve.

Availability: NAMKind™ liver and small intestine services are now being offered via JCBio and Tekon Biotech in Korea and China, with VivoSim set to further scale its platform’s reach.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI